Zheng is planning a clinical trial to see if it could work for post-stem
cell transplant AML relapse patients as well.
Not exact matches
Targeting exhausted immune
cells may change the prognosis for patients with acute myeloid leukemia (
AML) relapse after a stem
cell transplant, according to Penn State College of Medicine researchers.
Zheng is currently investigating the trigger for T
cell exhaustion in
AML stem
cell transplant recipients.
A blood cancer characterized by the rapid growth of abnormal white blood
cells,
AML is typically treated with chemotherapy, in some cases followed by a stem
cell transplant.
• Subject is refractory to or relapsed after first - line
AML therapy (with or without hematopoietic stem
cell transplant (HSCT)-RRB-.
There was scant experimental evidence for this hypothesis until 1994, when John Dick and colleagues demonstrated that leukemia - initiating stem
cells (LSCs) present in the blood of leukemia patients may induce acute myelogenous leukemia (
AML) when
transplanted into severe combined immunodeficient mice (2).
Stem
cell transplants (SCT) can elicit long - term disease free survival, but this treatment presents risks for the largest subpopulation of
AML patients, the elderly.